Molbio Diagnostics Limited
Molbio Diagnostics Limited is a global point-of-care molecular diagnostics company known for its proprietary Truenat PCR platform, offering rapid diagnostic solutions for infectious and non-communicable diseases across 90+ countries.
Overview
About the Company
Molbio Diagnostics Limited, incorporated in October 2000, is a globally active point-of-care molecular diagnostics company focused on developing, manufacturing, and commercialising rapid diagnostic solutions for both infectious and non-communicable diseases. Its flagship offering is the proprietary 'Truenat' platform — a portable, battery-powered PCR-based system tailored for resource-limited environments that delivers accurate results within roughly one hour. The company provides molecular testing for more than 30 diseases through 43 diagnostic assays, covering conditions such as tuberculosis, COVID-19, HIV, Hepatitis B & C, and HPV. Through subsidiaries and strategic partnerships, it also offers radiology, digital pathology, and breast health screening services. Molbio operates six manufacturing facilities in India and distributes products across 90+ countries, serving government health programmes, diagnostic labs, hospitals, and international health organisations. As of March 31, 2026, the company had 1,225 permanent employees.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Capital expenditure for establishing research and development infrastructure, a Centre of Excellence, and associated office space, estimated at ₹125.12 crores.
- › Capital expenditure for procuring plant, machinery, and equipment for the Goa Unit I, Goa Unit II, and Visakhapatnam manufacturing units, estimated at ₹80.81 crores.
- › General corporate purposes.
✅ Strengths
- ✓ The Truenat platform is a proprietary, WHO-endorsed technology for rapid PCR-based molecular diagnostics, particularly for tuberculosis detection.
- ✓ Robust in-house research and development capabilities backed by an extensive global patent portfolio.
- ✓ A scalable business model driven by recurring revenues from consumable diagnostic test kits sold alongside installed Truenat devices.
- ✓ Established presence in over 90 countries with a strong, diversified base of government health programmes and institutional clients.
- ✓ Growth enhanced through strategic acquisitions and collaborations that broaden the diagnostics portfolio into radiology, digital pathology, and breast health screening.
- ✓ An experienced leadership team with deep domain expertise in molecular diagnostics and healthcare innovation.
⚠️ Risks
- ! A significant portion of revenues depends on procurement funding from government bodies and international aid agencies, creating concentration risk.
- ! Revenue mix is heavily skewed towards tuberculosis-related test kits, making the company vulnerable to changes in TB programme funding or policy.
- ! A small number of large customers account for a disproportionate share of total revenues.
- ! Delays in obtaining regulatory approvals can slow down the commercialisation of new diagnostic tests and impact growth.
- ! Demand is closely tied to public health policies and funding cycles, which can fluctuate and create revenue unpredictability.